PDL recently acquired the rights to two revenue streams, which may help its long-term cash flow position. Firstly, it signed a deal of up to $200m ($50m upfront) with Ariad for royalty rights to Iclusig, an approved oncology drug. Secondly, it signed a $65m deal (all upfront) with AcelRx for royalty rights for its sufentanil sublingual tablet system, Zalviso, which has just been approved in the EU and should launch in H116. The two products could provide total peak royalties of around $50m in
22 Oct 2015
Adding long-term revenue streams
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Adding long-term revenue streams
- Published:
22 Oct 2015 - Author:
- Pages:
PDL recently acquired the rights to two revenue streams, which may help its long-term cash flow position. Firstly, it signed a deal of up to $200m ($50m upfront) with Ariad for royalty rights to Iclusig, an approved oncology drug. Secondly, it signed a $65m deal (all upfront) with AcelRx for royalty rights for its sufentanil sublingual tablet system, Zalviso, which has just been approved in the EU and should launch in H116. The two products could provide total peak royalties of around $50m in